
AnaptysBio Earnings, Revenue miss In Q3
Investing.com - AnaptysBio reported on Tuesday third quarter {{erl-995702||earnings that missed analysts' forecasts and revenue that fell short of expectations. AnaptysBio announced...
Investing.com - AnaptysBio reported on Tuesday third quarter {{erl-995702||earnings that missed analysts' forecasts and revenue that fell short of expectations. AnaptysBio announced...
AnaptysBio Inc (NASDAQ: ANAB) - GSK plc (NYSE: GSK) partnered PERLA head-to-head trial of Jemperli vs. Keytruda for metastatic non-squamous non-small cell lung cancer, met its primary...
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancer COSTAR, a Phase 2 trial of...
Pre-Open Stock Movers:Okta, Inc. (NASDAQ:OKTA) 21% LOWER; reported Q2 EPS of ($0.10), $0.21 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $452 million...
After-Hours Stock Movers:Nutanix (NASDAQ:NTNX) 22% HIGHER; reported Q4 EPS of ($0.17), $0.21 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $385.5 million...
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Utilities, Telecoms and Financials sectors propelled shares higher while losses in the Technology, Healthcare...
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Healthcare, Technology and Consumer Services sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Utilities, Consumer Goods and Financials sectors propelled shares higher. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.